N@N

Noveko Obtains NIOSH Certification for its RD5-V Respirator

^{Published on 2011-06-10 05:31:05 - Market Wire}
 

MONTREAL, June 10, 2011 /CNW Telbec/ - Noveko International Inc. (TSX: EKO) (the "Company") is pleased to announce that its subsidiary Noveko Inc. ("Noveko") has obtained N95 certification from the U.S. National Institute for Occupational Safety and Health ("NIOSH") for its Noveko(TM) RD5-V respirator.

"We have completed a new milestone in our regulatory approval process, which represents an additional recognition of the effectiveness of our respirators. This certification confirms that they meet the NIOSH's particle filtration criteria as well as its design and manufacturing requirements in regard to quality assurance. Furthermore, because a number of buyers still seek NIOSH recognition in their purchasing decisions, we believe this approval will facilitate the marketing of all our antimicrobial masks and respirators, notably in Canada, even though it has been obtained for a "vanilla" respirator model without antimicrobial agents," indicated Mr. Alain Bolduc, President and Chief Operating Officer of the Company.

This certification for the Noveko(TM) RD5-V respirator adds to the FFP2 classification the Company previously obtained for its Noveko(TM) RD2 antimicrobial respirator allowing its marketing in European Union countries. The U.S. commercialization of respirators incorporating Noveko's antimicrobial technology still remains subject to obtaining FDA certification.

Profile

Noveko International Inc. offers innovative solutions in the environmental and medical fields worldwide. Through its subsidiaries, the Company specializes primarily in the following business segments: the development, manufacturing and marketing of derivative products from its patented antimicrobial filtration technologies, mainly air filters, surgical masks and respirators, as well as other products with antibacterial properties such as hand sanitizers - and the development, manufacturing and marketing of medical equipment, primarily portable real-time ultrasound scanners for use in human and veterinary medicine.

Certain statements set forth in this press release constitute forward-looking statements. In some cases, these statements are identified by the use of terms such as "may", "could", "might", "intend", "should", "expect", "project", "plan", "believe", "estimate" or other comparable variants. These statements are based on the information available at the time they are written, on assumptions made by management and on the expectations of management, acting in good faith, regarding future events, including those relating to economic conditions, fluctuations in exchange rates and operating expenses, and the absence of unusual events entailing supplementary expenditures. Although management considers these assumptions and expectations reasonable based on the information available at the time they are written, they could prove inaccurate. Forward-looking statements are also subject, by their very nature, to known and unknown risks and uncertainties such as those related to the industry, acquisitions, labor relations, credit, key officers, supply and product liability. The actual results of Noveko International Inc. could differ materially from those indicated or underlying these forward-looking statements. The reader is therefore recommended not to unduly rely on these forward-looking statements. Forward-looking statements do not reflect the potential impact of special items, any business combination or any other transaction that may be announced or occur subsequent to the date hereof. Unless otherwise required under securities laws, the Company does not intend and undertakes no obligation to update or revise the forward-looking statements.